Literature DB >> 14559803

Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.

Weiguo Wu1, Brian M Slomovitz, Joseph Celestino, Linda Chung, Angela Thornton, Karen H Lu.   

Abstract

Overexpression of cdc25B, an important cell cycle regulator, has been shown to result in mammary gland hyperplasia in transgenic mice and to increase steroid hormone responsiveness as a direct coactivator of the estrogen receptor (ER). We investigated the potential role of cdc25B in the pathogenesis of endometrial carcinomas in conjunction with ER-alpha. We examined the expression of cdc25B and phosphorylated ER-alpha in 4 archived human specimens of normal endometrium; 7 endometrial hyperplasia with or without atypia; 32 endometrioid endometrial carcinoma (EEC), including 20 low-grade (grade 1) and 12 high-grade (grade 2 or 3) tumors; and 18 endometrial cancers with aggressive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by immunohistochemistry with monoclonal antibodies. Expression of cdc25B and phosphorylated ER-alpha was increased in endometrial hyperplasia and atypical hyperplasia compared with normal secretory endometrium. Ninety percent (18 of 20) of the low-grade EEC expressed cdc25B at a high level, whereas only 42% (5 of 12) of the high-grade EEC did so (chi(2) = 8.7; P < 0.01). Sixty-five percent (13 of 20) of the low-grade EEC expressed phosphorylated ER-alpha at high levels, but only 17% (2 of 12) of high-grade EEC did so (chi(2) = 7.0; P < 0.01). Coordinate high-level expression of phosphorylated ER-alpha and cdc25B occurred in 65% (13 of 20) of low-grade EEC but in only 17% (2 of 12) of the high-grade EEC (chi(2) = 7.0; P < 0.01). In the UPSC/CCC tumors, only 22% (4 of 18) of the tumors expressed phosphorylated ER-alpha at high-levels. However, 83% (15 of 18) of these carcinomas showed high expression of cdc25B (chi(2) = 13.5; P < 0.01). The majority of the UPSC/CCC (15 of 18) did not show coordinate high expression of phosphorylated ER-alpha and cdc25B. Our findings show that in endometrial hyperplasia and low-grade EEC, coordinate increase in cdc25B and phosphorylated ER-alpha occurs. However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-alpha. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14559803

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities.

Authors:  I A Voutsadakis
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  Survival outcomes in endometrial cancer patients are associated with CXCL12 and estrogen receptor expression.

Authors:  Ashley S Felix; Roslyn A Stone; Mamatha Chivukula; Robert Bowser; Anil V Parwani; Faina Linkov; Robert P Edwards; Joel L Weissfeld
Journal:  Int J Cancer       Date:  2012-01-03       Impact factor: 7.396

Review 3.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

4.  High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder.

Authors:  Zhe Zhang; Guojun Zhang; Chuize Kong
Journal:  Tumour Biol       Date:  2014-03

5.  Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.

Authors:  Jian-Zhong Shou; Nan Hu; Mikiko Takikita; Mark J Roth; Laura Lee Johnson; Carol Giffen; Quan-Hong Wang; Chaoyu Wang; Yuan Wang; Hua Su; Li-Hui Kong; Michael R Emmert-Buck; Alisa M Goldstein; Stephen M Hewitt; Philip R Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-06       Impact factor: 4.254

6.  METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression.

Authors:  Yu-Qing Guo; Qiang Wang; Jun-Guo Wang; Ya-Jun Gu; Pan-Pan Song; Shou-Yu Wang; Xiao-Yun Qian; Xia Gao
Journal:  Exp Hematol Oncol       Date:  2022-03-14

7.  Overexpression of claudin-4 may be involved in endometrial tumorigenesis.

Authors:  Xiao-Yu Pan; Xue Li; Yan-Ci Che; Hong-Yan Li; Xin Li; Yun Zhang; Xin Yang
Journal:  Oncol Lett       Date:  2013-02-18       Impact factor: 2.967

8.  Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.

Authors:  Yu-Wei Chou; Li Zhang; Sakthivel Muniyan; Humera Ahmad; Satyendra Kumar; Syed Mahfuzul Alam; Ming-Fong Lin
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.